Skip to content
Search

Latest Stories

Submit Guest Post

J&J Covid-19 shots expected to be imported to India by July, says report

J&J Covid-19 shots expected to be imported to India by July, says report

Johnson and Johnson's single-shot Covid-19 vaccine is expected to be imported to India for "fill and finish" by June or July, as reported by an Indian financial daily on Friday (23).

Fill and finish is the final step in the manufacturing process of putting the vaccine into vials or syringes, sealing them and packaging them up for shipping.


India has said it would fast-track emergency approvals for Covid-19 vaccines authorised by western countries and Japan, paving the way for possible imports of Pfizer, Johnson & Johnson and Moderna shots.

This will exempt companies from carrying out local safety trials for their vaccines.

India recorded the world's highest daily tally of coronavirus cases for a second day in a row on Friday (23) with 332,730 new cases, while daily deaths from Covid-19 also jumped by a record.

"The Johnson & Johnson vaccines are expected to be imported to India by June-July 2021. Johnson & Johnson is working closely with Biological E to facilitate the ongoing tech transfer to India," Renu Swarup, secretary, Department of Biotechnology, Ministry of Science and Technology, told Reuters partner ANI on Thursday (22).

Pharmaceutical company Biological E Ltd had told Reuters in February it was looking to contract-manufacture roughly 600 million doses of Johnson and Johnson's Covid-19 vaccine annually.

The Department of Biotechnology, Ministry of Science and Technology and a local representative for J&J did not immediately respond to Reuters requests for comment.

Add EasternEye As Your Trusted Source
preferred source on google news

More For You

Deepinder Goyal

Temple is rewarding early employees as the wearable technology startup gains investor momentum

X handle

Zomato founder's wearable startup Temple doubles in value ahead of launch

  • Temple's valuation has reportedly climbed to $375 million, nearly double its previous $190 million valuation.
  • Around 20 employees will be eligible to sell up to 25 per cent of their vested ESOPs.
  • The startup is preparing for the commercial launch of its health wearable device after raising $54 million in seed funding.

Temple, the wearable technology startup founded by Deepinder Goyal, has reportedly nearly doubled its valuation to $375 million while giving some of its earliest employees an opportunity to cash out part of their stock options.

According to a Moneycontrol report, the company has launched its first employee stock ownership plan (ESOP) liquidity programme, allowing eligible employees to sell a portion of their vested shares at the new valuation. The move comes as Temple prepares for its commercial launch and attracts growing investor interest ahead of its next fundraising round.

Keep ReadingShow less